
Gritstone bio, Inc.
- Jurisdiction
United States - LEI
5493003TER6KY3MUVY84 - ISIN
US39868T1051 (GRTS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€1.46M - Gross margin
-325.1% - EBIT
-€128.16M - EBIT margin
-8,786.8% - Net income
-€114.14M - Net margin
-7,825.5%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 9, 2024